Abstract
Introduction: One of the key action areas of the World Health Organization (WHO) third Global Patient Safety Challenge ‘Medication Without Harm’ (WHO, 2017) is to reduce severe avoidable medication-related harm and address polypharmacy. NICE guidance on falls risk assessment and prevention also includes medication review as part of its recommended multifactorial risk assessment (NICE, 2013). Use of Falls Risk Increasing Drugs (FRIDs), along with polypharmacy and anticholinergic burden (ACB) are known to increase the risk of falls, particularly in older people.
Method:
This research quantitatively evaluates the impact of the intervention of a novel community falls pharmacist role on medicines optimisation, in relation to FRIDs in older people who have had a fall. We will present data on admission and discharge from the service in relation to:
- Number and type of FRIDs prescribed
- Calculation of Anticholinergic Burden score using the ACBcalc® (King and Rabino, 2022)
- Polypharmacy- number of medications prescribed
- The appropriateness of medicines prescribed
- Undertake measurement of lying/ standing manual blood pressure to identify potential postural drop in blood pressure, and hypertension.
- Undertake a Bone health review using an approved tool (FRAX)
- Outcome of pharmacist referral of appropriate patients for DEXA scan using a new direct referral system
- Measure the significance of clinical interventions (EADON graded)
- Calculate the cost avoidance of pharmacist interventions (ScHARR Tool) Results
Results:
Data was collected on 92 patients over 14 months. Results indicate a medicines review by the community falls pharmacist leads to a statistically significant reduction in polypharmacy (¯8%; p<0.05) and ACB (¯33%; p<0.05), an increased appropriateness of prescribing (MAI ¯56%; p<0.05), 317 clinically significant interventions, identification of blood pressure issues (22%) eg orthostatic hypotension, and identification of osteopenia (n=13) or osteoporosis (n=4) using a new pharmacist DEXA referral pathway. Amitriptyline was the most common FRID deprescribed (22%). Annual cost avoidance due to pharmacist interventions were in the range of £28160 – £62358 along with drug cost savings of £6041, amounting to total savings of £34201-£68400, and invest to save return of one to two pounds for every £1 invested. Benefit to the environment of reduced inappropriate prescribing amounted to almost 1 tonne of avoidable CO2 emissions per year.
Conclusion:
Introduction of a community falls pharmacist role is an effective and cost efficient means to optimise medicines in older people who experience falls, as well as having a positive impact on the environment.